During the past decade, Universita di Pisa conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universita di Pisa" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials, followed by "Amgen" with 1 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Belgian Gynaecological Oncology Group" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universita di Pisa" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "European Commission" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator, "Grupo Español de Investigación en Cáncer de Ovario" with 1 trials as a collaborator and "Mario Negri Gynecologic Oncology group (MaNGO)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Universita di Pisa" are "Bladder Cancer" (2 trials), "Acromegaly" (1 trials), "Alzheimer´s Disease" (1 trials), "Atrial Fibrillation New Onset" (1 trials) and "Bacteremia Caused by Gram-Negative Bacteria" (1 trials). Many other conditions were trialed in "Universita di Pisa" in a lesser frequency.

Most popular intervention types in "Universita di Pisa" are "Drug" (8 trials), "Biological" (2 trials), "Device" (2 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "BCG vaccine" (2 trials), "Apremilast 20mg" (1 trials), "Apremilast 30mg" (1 trials) and "Ceftolozane-Tazobactam" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universita di Pisa" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Universita di Pisa". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Universita di Pisa, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universita di Pisa, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Universita di Pisa has several departments that took part in Clinical trials: "Department of Clinical and Experimental Medicine, University of Pisa" - 4 trials